Get started
Author

Wolfgang Hoeltl

European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus group (EGCCCG): Part I
2008 · Susanne Krege, Jörg Beyer, et al. · European Urology · 621
Final Results of an EORTC-GU Cancers Group Randomized Study of Maintenance Bacillus Calmette-Guérin in Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Urinary Bladder: One-third Dose Versus Full Dose and 1 Year Versus 3 Years of Maintenance
2012 · Jorg Oddens, Maurizio Brausi, et al. · European Urology · 528
European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG)
2004 · H.J. Schmoll, R. Souchon, et al. · Annals of Oncology · 507
PDF
Long-Term Efficacy Results of EORTC Genito-Urinary Group Randomized Phase 3 Study 30911 Comparing Intravesical Instillations of Epirubicin, Bacillus Calmette-Guérin, and Bacillus Calmette-Guérin plus Isoniazid in Patients with Intermediate- and High-Risk Stage Ta T1 Urothelial Carcinoma of the Bladder
2009 · Richard J. Sylvester, Maurizio A. Brausi, et al. · European Urology · 441
Maintenance Bacillus Calmette-Guerin for Ta T1 Bladder Tumors Is Not Associated with Increased Toxicity: Results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial
2003 · Adrian P.M. van der Meijden, Richard J. Sylvester, et al. · European Urology · 304
European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): Part II
2008 · Susanne Krege, Jörg Beyer, et al. · European Urology · 257
Management of prostate-specific antigen relapse in prostate cancer: A European consensus
2004 · L. Boccon-Gibod, B. Djavan, et al. · International Journal of Clinical Practice · 130
PDF
Intravesical BCG in Patients with Carcinoma in situ of the Urinary Bladder: Long–Term Results of EORTC GU Group Phase II Protocol 30861
2001 · G. Jakse, R. Hall, et al. · European Urology · 102
Renal Vein Anatomy and its Implications for Retroperitoneal Surgery
1990 · Wolfgang Hoeltl, Walter Hruby, et al. · The Journal of Urology · 91
The Side Effects of Bacillus Calmette-Guerin in the Treatment of Ta T1 Bladder Cancer Do Not Predict its Efficacy: Results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial
2003 · Richard J. Sylvester, Adrian P.M. van der Meijden, et al. · European Urology · 89
Effect of NIH-IV Prostatitis on Free and Free-to-total PSA
2004 · Igor Stancik, Werner Lüftenegger, et al. · European Urology · 67
Testicular Cancer: Prognostic Implications of Vascular Invasion
1987 · W. Hoeltl, D. Kosak, et al. · The Journal of Urology · 41
Prevalence and Incidence of Clinical Symptoms of the Retroaortic Left Renal Vein
2015 · Stefan Heidler, Stephan Hruby, et al. · Urologia Internationalis · 27
Treatment Decision for Stage I Non‐seminomatous Germ Cell Tumours Based on the Risk Factor “Vascular Invasion”
1992 · W. HOELTL, J. PONT, et al. · British Journal of Urology · 21
How Effective is Topical Alpha‐2b Interferon in Preventing Recurrence of Superficial Bladder Cancer?
1991 · W. HOELTL, R. HASUN, et al. · British Journal of Urology · 19
Long-term Efficacy Results of Eortc Gu Group Study 30911 Comparing Epirubicin, Bacillus Calmetteguerin (bcg), and Bcg Plus Isoniazid in Patients With Intermediate and High Risk Stage Ta T1 Papillary Carcinoma of the Bladder
2008 · R.J. Sylvester, M.A. Brausi, et al. · European Urology Supplements · 13
PSA testing in Austria: induced morbidity and saved mortality
2009 · Christian Vutuc, Thomas Waldhoer, et al. · European Journal of Cancer Prevention · 9
1050 Bacillus Calmette-Guerin: One third dose versus full dose and one year versus three years of maintenance. Final results of an EORTC GU Cancers Group randomized trial in non muscle invasive bladder cancer
2012 · M.A. Brausi, J.R. Oddens, et al. · European Urology Supplements · 8
Corrigendum to: “European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus group (EGCCCG): Part I” [Eur Urol 2008;53:478–96] and to: “European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus group (EGCCCG): Part II” [Eur Urol 2008;53:497–513]
2008 · Susanne Krege, Jörg Beyer, et al. · European Urology · 8
Prospective, randomized trial to evaluate high-versus low-dose interferon-α2b versus conventional chemotherapy in prevention of the recurrence of superficial transitional cell carcinoma of the urinary bladder
1992 · W Hoeltl, R Hasun, et al. · Anti-Cancer Drugs · 7
Asynchronous bilateral testicular tumour without previous carcinoma in situ
1991 · W. Hoeltl, Ch. Gabriel, et al. · European Journal of Cancer and Clinical Oncology · 7
Surgical Approach to the Retrocrural Lymph Nodes
1990 · W. HOELTL, S. AHARINEJAD · British Journal of Urology · 5
1665 Bacillus Calmette-guerin One Third Dose Versus Full Dose and One Year Versus Three Years of Maintenance. Final Results of Eortc Gu Cancers Group Randomized Trial 30962 in Non Muscle Invasive Bladder Cancer
2012 · Maurizio Brausi, Jorg Oddens, et al. · The Journal of Urology · 3
What is the benfit of mTOR inhibitors (mTORi) rechallenge in metastatic renal clear cell carcinoma (mRCC) patients (pts) initially treated with TKI?
2012 · Agnes Maj-HES, Reza-Thierry Elaidi, et al. · Journal of Clinical Oncology · 3
Maintenance bacillus calmette-guerin for TA, T1 bladder cancer is not associated with increased toxicity, results from an eortc genito-urinary group phase III trial
2003 · A. Van der Meijden, R. Sylvester, et al. · European Urology Supplements · 3
Works count: 33
Citation count: 3,312
H-index: 15
I10-index: 16
Year
Topic
Type